Research programme: cancer antibody therapies - Celera/Seattle Genetics

Drug Profile

Research programme: cancer antibody therapies - Celera/Seattle Genetics

Latest Information Update: 03 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celera Genomics Group; Seattle Genetics
  • Developer Celera Corporation; Seattle Genetics
  • Class Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 20 Jun 2005 This programme is still in active development
  • 29 Jul 2004 Celera Genomics and Seattle Genetics have entered into an agreement to co-develop targeted antibody therapies in USA for cancer
  • 29 Jul 2004 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top